Form 4 for MAZE Maze Therapeutics, Inc.
Accepted 2026-04-01 16:12:33 ET · period of report 2026-03-30 · accession 0002050167-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-01 16:12 | 2026-03-30 | MAZE | Dandekar Atul | CSBO | M - OptEx | $10.42 | +7,500 | 18.0K | +71% | +$78.2K |
| DMT | 2026-04-01 16:12 | 2026-03-30 | MAZE | Dandekar Atul | CSBO | S - Sale+OE | $29.34 | -7,500 | 10.5K | -42% | -$220.0K |
| DT | 2026-04-01 16:12 | 2026-03-30 | MAZE | Dandekar Atul | CSBO | M - OptEx | $0.00 | -7,500 | 51.6K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-30 | M | A | 7,500 | $10.42 | 18,003 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. |
| 2 | Common | Common Stock | 2026-03-30 | S | D | 6,710 | $29.26 | 11,293 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.86 to $29.84 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
| 3 | Common | Common Stock | 2026-03-30 | S | D | 790 | $30.02 | 10,503 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.87 to $30.24 per share, inclusive. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-03-30 | M | D | 7,500 | $0.00 | 51,643 | D | $10.42 · — to 2031-04-11 | 7,500 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. (F4) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. |